Connect with us
Rovi has gained FDA approval for its drug Risvan to treat schizophrenia in adults. The approval led to a nearly 3% surge in Rovi's stock. Risvan,...
Of the Spanish pharma listed companies, PharmaMar has suffered the most significant drop in profits due to generic drug competition with its star drug. Rovi has...
The partnership with Moderna has been very fruitful for Rovi: the laboratory has gone from earning 65.6 million euros in third-party manufacturing in 2019 to billing...
Spanish pharma companies started the year maintaining the red of the previous year. In Q1, the aggregate capitalization registered a drop of 10.57%, with values such...
The gross operating result (Ebitda) reached €97.1 million in the first half of 2023, 16% less than in the first six months of 2022. Operating income...
Rovi announced that it estimates its operating income will decrease by around 10% compared to 2023. This forecast has been justified, mainly, by the fact that...
Rovi obtained a gross operating result of €279 million in 2022. Sales of the heparin division increased by 9% in 2022 compared to 2021, up to...
The Spanish pharma sector increased 5% on the stock market in the first quarter despite the fall of Grifols. Pharma Mar was the pharmaceutical company with...